Dr Elaine Butterly

  • Clinical Research Fellow (Public Health)

Biography

Dr Elaine Butterly graduated in 2011 from the University of Glasgow with MBChB with honours. This followed from a BSc(Med Sci) intercalated degree in 2009 in Developmental Medicine.

Since graduation she has worked in clinical training in the NHS, now dual accrediting in higher specialist training in Diabetes and Endocrinology and General Internal Medicine. In 2014 she achieved membership of the Royal College of Physicians (MRCP) Glasgow and has since completed the Speciality Certificate Exam (SCE) in Endocrinology and Diabetes through MRCPUK. She continues focused clinical work through an honorary contract with NHS Greater Glasgow and Clyde.

She joined the Institute of Health and Wellbeing in February 2019 as a Clinical Research Fellow within the Public Health Department focusing particular interests in the field of type 2 diabetes.

Publications

List by: Type | Date

Jump to: 2023 | 2022 | 2021 | 2020
Number of items: 10.

2023

Butterly, E. W. et al. (2023) Comorbidity and health-related quality of life in people with a chronic medical condition in randomised clinical trials: an individual participant data meta-analysis. PLoS Medicine, 20(1), e1004154. (doi: 10.1371/journal.pmed.1004154)

2022

Hanlon, P. , Butterly, E., Shah, A. S. V., Hannigan, L. J. , Wild, S. H., Guthrie, B., Mair, F. S. , Dias, S., Welton, N. J. and McAllister, D. A. (2022) Assessing trial representativeness using Serious Adverse Events: An observational analysis using aggregate and individual-level data from clinical trials and routine healthcare data. BMC Medicine, 20, 410. (doi: 10.1186/s12916-022-02594-9) (PMID:36303169) (PMCID:PMC9615407)

Butterly, E. et al. (2022) Calibrating a network meta-analysis of diabetes trials of sodium glucose cotransporter 2 inhibitors, glucagon-like peptide-1 receptor analogues and dipeptidyl peptidase-4 inhibitors to a representative routine population: a systematic review protocol. BMJ Open, 12(10), e066491. (doi: 10.1136/bmjopen-2022-066491) (PMID:36302574) (PMCID:PMC9621152)

Hannigan, L. J. , Phillippo, D. M., Hanlon, P. , Moss, L. , Butterly, E. W., Hawkins, N. , Dias, S., Welton, N. J. and McAllister, D. A. (2022) Improving the estimation of subgroup effects for clinical trial participants with multimorbidity by incorporating drug class-level information in Bayesian hierarchical models: a simulation study. Medical Decision Making, 42(2), pp. 228-240. (doi: 10.1177/0272989X211029556) (PMID:34407672) (PMCID:PMC8777306)

Lees, J. S. et al. (2022) Effect of age, sex, and morbidity count on trial attrition: meta-analysis of individual participant level data from phase 3/4 industry funded clinical trials. BMJ Medicine, 1(1), e000217. (doi: 10.1136/bmjmed-2022-000217)

2021

Hanlon, P. , Jani, B. D. , Butterly, E., Nicholl, B. , Lewsey, J. , McAllister, D. A. and Mair, F. S. (2021) An analysis of frailty and multimorbidity in 20,566 UK Biobank participants with type 2 diabetes. Communications Medicine, 1, 28. (doi: 10.1038/s43856-021-00029-9)

McGurnaghan, S. J. et al. (2021) Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland. Lancet Diabetes and Endocrinology, 9(2), pp. 82-93. (doi: 10.1016/S2213-8587(20)30405-8) (PMID:33357491) (PMCID:PMC7832778)

2020

Hanlon, P. , Faure, I., Corcoran, N. , Butterly, E., Lewsey, J. , McAllister, D. and Mair, F. S. (2020) Frailty measurement, prevalence, incidence, and clinical implications in people with diabetes: a systematic review and study-level meta-analysis. Lancet Healthy Longevity, 1(3), e106-e116. (doi: 10.1016/S2666-7568(20)30014-3) (PMID:33313578) (PMCID:PMC7721684)

Hanlon, P. , Butterly, E., Lewsey, J. , Siebert, S. , Mair, F. S. and McAllister, D. A. (2020) Identifying frailty in trials: an analysis of individual participant data from trials of novel pharmacological interventions. BMC Medicine, 18, 309. (doi: 10.1186/s12916-020-01752-1) (PMID:33087107) (PMCID:PMC7579922)

Hanlon, P. , Fauré, I., Corcoran, N. , Butterly, E., Lewsey, J. , McAllister, D. A. and Mair, F. S. (2020) The identification and prevalence of frailty in diabetes mellitus and association with clinical outcomes: a systematic review protocol. BMJ Open, 10(9), e037476. (doi: 10.1136/bmjopen-2020-037476) (PMID:32873673) (PMCID:PMC7467518)

This list was generated on Tue Jan 31 08:17:52 2023 GMT.
Jump to: Articles
Number of items: 10.

Articles

Butterly, E. W. et al. (2023) Comorbidity and health-related quality of life in people with a chronic medical condition in randomised clinical trials: an individual participant data meta-analysis. PLoS Medicine, 20(1), e1004154. (doi: 10.1371/journal.pmed.1004154)

Hanlon, P. , Butterly, E., Shah, A. S. V., Hannigan, L. J. , Wild, S. H., Guthrie, B., Mair, F. S. , Dias, S., Welton, N. J. and McAllister, D. A. (2022) Assessing trial representativeness using Serious Adverse Events: An observational analysis using aggregate and individual-level data from clinical trials and routine healthcare data. BMC Medicine, 20, 410. (doi: 10.1186/s12916-022-02594-9) (PMID:36303169) (PMCID:PMC9615407)

Butterly, E. et al. (2022) Calibrating a network meta-analysis of diabetes trials of sodium glucose cotransporter 2 inhibitors, glucagon-like peptide-1 receptor analogues and dipeptidyl peptidase-4 inhibitors to a representative routine population: a systematic review protocol. BMJ Open, 12(10), e066491. (doi: 10.1136/bmjopen-2022-066491) (PMID:36302574) (PMCID:PMC9621152)

Hannigan, L. J. , Phillippo, D. M., Hanlon, P. , Moss, L. , Butterly, E. W., Hawkins, N. , Dias, S., Welton, N. J. and McAllister, D. A. (2022) Improving the estimation of subgroup effects for clinical trial participants with multimorbidity by incorporating drug class-level information in Bayesian hierarchical models: a simulation study. Medical Decision Making, 42(2), pp. 228-240. (doi: 10.1177/0272989X211029556) (PMID:34407672) (PMCID:PMC8777306)

Lees, J. S. et al. (2022) Effect of age, sex, and morbidity count on trial attrition: meta-analysis of individual participant level data from phase 3/4 industry funded clinical trials. BMJ Medicine, 1(1), e000217. (doi: 10.1136/bmjmed-2022-000217)

Hanlon, P. , Jani, B. D. , Butterly, E., Nicholl, B. , Lewsey, J. , McAllister, D. A. and Mair, F. S. (2021) An analysis of frailty and multimorbidity in 20,566 UK Biobank participants with type 2 diabetes. Communications Medicine, 1, 28. (doi: 10.1038/s43856-021-00029-9)

McGurnaghan, S. J. et al. (2021) Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland. Lancet Diabetes and Endocrinology, 9(2), pp. 82-93. (doi: 10.1016/S2213-8587(20)30405-8) (PMID:33357491) (PMCID:PMC7832778)

Hanlon, P. , Faure, I., Corcoran, N. , Butterly, E., Lewsey, J. , McAllister, D. and Mair, F. S. (2020) Frailty measurement, prevalence, incidence, and clinical implications in people with diabetes: a systematic review and study-level meta-analysis. Lancet Healthy Longevity, 1(3), e106-e116. (doi: 10.1016/S2666-7568(20)30014-3) (PMID:33313578) (PMCID:PMC7721684)

Hanlon, P. , Butterly, E., Lewsey, J. , Siebert, S. , Mair, F. S. and McAllister, D. A. (2020) Identifying frailty in trials: an analysis of individual participant data from trials of novel pharmacological interventions. BMC Medicine, 18, 309. (doi: 10.1186/s12916-020-01752-1) (PMID:33087107) (PMCID:PMC7579922)

Hanlon, P. , Fauré, I., Corcoran, N. , Butterly, E., Lewsey, J. , McAllister, D. A. and Mair, F. S. (2020) The identification and prevalence of frailty in diabetes mellitus and association with clinical outcomes: a systematic review protocol. BMJ Open, 10(9), e037476. (doi: 10.1136/bmjopen-2020-037476) (PMID:32873673) (PMCID:PMC7467518)

This list was generated on Tue Jan 31 08:17:52 2023 GMT.